European Medical Solutions (LTS:0RGO) LT-Debt-to-Total-Asset : 0.26 (As of Jun. 2024)

View and export this data going back to 2016. Start your Free Trial

What is European Medical Solutions LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. European Medical Solutions's long-term debt to total assests ratio for the quarter that ended in Jun. 2024 was 0.26.

European Medical Solutions's long-term debt to total assets ratio increased from Jun. 2023 (0.24) to Jun. 2024 (0.26). It may suggest that European Medical Solutions is progressively becoming more dependent on debt to grow their business.

European Medical Solutions LT-Debt-to-Total-Asset Historical Data

The historical data trend for European Medical Solutions's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

European Medical Solutions LT-Debt-to-Total-Asset Chart

European Medical Solutions Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.25

0.27

0.30

European Medical Solutions Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.29	0.27	0.24	0.30	0.26

European Medical Solutions LT-Debt-to-Total-Asset Calculation

European Medical Solutions's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	13.067	/	43.758
	=	0.30

European Medical Solutions's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jun. 2024 is calculated as

LT Debt to Total Assets (Q: Jun. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Jun. 2024 )	/	Total Assets (Q: Jun. 2024 )
	=	11.697	/	45.237
	=	0.26

European Medical Solutions (LTS:0RGO) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

European Medical Solutions LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of European Medical Solutions's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

European Medical Solutions Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » European Medical Solutions (LTS:0RGO) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

ALEMS:Belgium

Address

7 Rue des Chasseurs Ardennais, Liege, BEL, 4031

Website

https://www.dms-imaging.com

European Medical Solutions Formerly DMS Imaging SA is a clinical-stage biopharmaceutical company. The company is engaged in the development and future commercialization of a range of breakthrough immunotherapy products for the treatment of allergies, based on its ASIT+ technology platform. Its lead product is gp-ASIT+, a phase III trial for the treatment of grass pollen rhinitis. Its pipeline products consist of hdm-ASIT+ for the treatment of house dust mite asthma; and pnt-ASIT+ for the treatment of peanut allergy.

European Medical Solutions Headlines

No Headlines